Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab) for Relapsed/Refractory Multiple Myeloma
[FDA Approval] BCMA/CD3 Bispecific Antibody Approved on July 2, 2025 On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab (brand name: Lynozyfic) for the treatment of adults with rela...
